236 related articles for article (PubMed ID: 23440162)
21. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Matarasso A; Shafer D
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
[TBL] [Abstract][Full Text] [Related]
22. A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice.
Karschney VK; Greeley DR
Am Health Drug Benefits; 2020; 13(5):205-210. PubMed ID: 33343821
[TBL] [Abstract][Full Text] [Related]
23. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
[TBL] [Abstract][Full Text] [Related]
24. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke.
Santamato A; Micello MF; Ranieri M; Valeno G; Albano A; Baricich A; Cisari C; Intiso D; Pilotto A; Logroscino G; Panza F
J Neurol Sci; 2015 Mar; 350(1-2):1-6. PubMed ID: 25684341
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin A injections in children: technique and dosing issues.
Kinnett D
Am J Phys Med Rehabil; 2004 Oct; 83(10 Suppl):S59-64. PubMed ID: 15448579
[TBL] [Abstract][Full Text] [Related]
26. Diffusion of aniline blue injected into the thyroarytenoid muscle as a proxy for botulinum toxin injection: an experimental study in cadaver larynges.
Alonso VM; Chagury AA; Hachiya A; Imamura R; Tsuji DH; Sennes LU
Int Arch Otorhinolaryngol; 2013 Jul; 17(3):315-20. PubMed ID: 25992028
[TBL] [Abstract][Full Text] [Related]
27. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
28. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
29. IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials.
Prager W; Nogueira Teixeira D; Leventhal PS
Dermatol Surg; 2017 Jul; 43(7):959-966. PubMed ID: 28375973
[TBL] [Abstract][Full Text] [Related]
30. Botulinum toxin injection, dilution confusion: The impact of toxin diffusion on clinical practice.
Davis T
J Pediatr Rehabil Med; 2020; 13(2):201-204. PubMed ID: 32568126
[TBL] [Abstract][Full Text] [Related]
31. Botulinum toxin type A products are not interchangeable: a review of the evidence.
Brin MF; James C; Maltman J
Biologics; 2014; 8():227-41. PubMed ID: 25336912
[TBL] [Abstract][Full Text] [Related]
32. Effect of volume and concentration on the diffusion of botulinum exotoxin A.
Hsu TS; Dover JS; Arndt KA
Arch Dermatol; 2004 Nov; 140(11):1351-4. PubMed ID: 15545544
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.
Carr WW; Jain N; Sublett JW
Adv Ther; 2021 Oct; 38(10):5046-5064. PubMed ID: 34515975
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.
Ferrari A; Manca M; Tugnoli V; Alberto L
Funct Neurol; 2018; 33(1):7-18. PubMed ID: 29633692
[TBL] [Abstract][Full Text] [Related]
35. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.
Frevert J
Drugs R D; 2015 Mar; 15(1):1-9. PubMed ID: 25559581
[TBL] [Abstract][Full Text] [Related]
36. Botulinum Toxin Type A Immunogenicity across Multiple Indications: An Overview Systematic Review.
Rahman E; Banerjee PS; Asghar A; Gupta NK; Mosahebi A
Plast Reconstr Surg; 2022 Apr; 149(4):837-848. PubMed ID: 35139064
[TBL] [Abstract][Full Text] [Related]
37. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
Bensmail D; Hanschmann A; Wissel J
J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
39. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
Lorenzano C; Bagnato S; Gilio F; Fabbrini G; Berardelli A
Neurotox Res; 2006 Apr; 9(2-3):141-4. PubMed ID: 16785111
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
